← All trials
NCT04785326
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Nov 30, 2022
- First posted
- Mar 5, 2021
- Last posted
- Nov 30, 2021
- Enrollment
- 605
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dong-A PharmaceuticalLead sponsor
- Meiji Seika Pharma Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.